Open AccessPractical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling
Author(s) -
Sandeep Aggarwal,
Ashok Vaid,
Anuradha Ramesh,
Purvish M. Parikh,
Sharad Purohit,
B Avasthi,
Sumiti Gupta,
Subhash Ranjan,
Vikrant Kaushal,
Sarwat Salim,
Ramvir Singh,
S. Minhas,
Dinesh Chandra Doval
Publication year - 2018
Publication title -
south asian journal of cancer
Language(s) - English
Resource type - Journals
eISSN - 2278-4306
pISSN - 2278-330X
DOI - 10.4103/sajc.sajc_110_18
Subject(s) - medicine , breast cancer , adjuvant chemotherapy , oncology , chemotherapy , stage (stratigraphy) , disease , expert opinion , consensus conference , gynecology , cancer , intensive care medicine , paleontology , biology
Breast cancer is a heterogeneous disease and patients are managed clinically based on ER, PR, HER2 expression, and key risk factors. The use of gene expression assays for early stage disease is already common practice. These tests have found a place in risk stratifying the heterogeneous group of stage I–II breast cancers for recurrence, for predicting chemotherapy response, and for predicting breast cancer-related mortality. Most guidelines for hormone receptor (HR)–positive early breast cancer recommend addition of adjuvant chemotherapy for most women, leading to overtreatment, which causes considerable morbidity and cost. Expert oncologist discussed about strategies of gene expression assays and aid in chemotherapy recommendations for treatment of HR + ve EBC and the expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.